Polyrizon starts naloxone preclinical studies for opioid overdose
Ticker: PLRZ · Form: 6-K · Filed: Mar 10, 2025 · CIK: 1893645
| Field | Detail |
|---|---|
| Company | Polyrizon Ltd. (PLRZ) |
| Form Type | 6-K |
| Filed Date | Mar 10, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: drug-development, preclinical-studies, opioid-crisis, naloxone
TL;DR
Polyrizon initiating preclinical studies for intranasal naloxone to combat opioid overdose.
AI Summary
Polyrizon Ltd. announced on March 10, 2025, the initiation of preclinical studies for an intranasal naloxone product designed to target opioid overdose. This development is based on their proprietary T&T Platform. The company is a foreign private issuer filing a Form 6-K with the SEC.
Why It Matters
This filing indicates Polyrizon is advancing its drug development pipeline, potentially addressing the critical issue of opioid overdose with a new delivery method.
Risk Assessment
Risk Level: medium — Preclinical studies are early-stage and carry inherent risks of failure before reaching market approval.
Key Players & Entities
- Polyrizon Ltd. (company) — Registrant
- March 10, 2025 (date) — Press release date
- Naloxone (drug) — Intranasal product target
- Opioid Overdose (medical_condition) — Target condition
- T&T Platform (technology) — Proprietary platform
- Form 6-K (filing) — SEC filing type
- Form S-8 (filing) — Incorporated registration statement
- 333-284410 (filing_number) — Form S-8 file number
FAQ
What is the specific goal of the preclinical studies for intranasal naloxone?
The preclinical studies aim to develop an intranasal naloxone product targeting opioid overdose, based on Polyrizon's T&T Platform.
When was the press release announcing these studies issued?
The press release was issued on March 10, 2025.
What is Polyrizon Ltd.'s primary business sector?
Polyrizon Ltd. is in the Pharmaceutical Preparations sector (SIC code 2834).
Which SEC filing form is incorporated by reference into the Form 6-K?
The Registrant's Registration Statement on Form S-8 (File No. 333-284410) is incorporated by reference.
Where is Polyrizon Ltd. headquartered?
Polyrizon Ltd. is headquartered in Raanana, Israel.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on March 10, 2025 regarding Polyrizon Ltd. (PLRZ).